From October 2-4th, SungenBio participated in 2019 Hi Japan, and was also invited to hold a symposium on vitamin K2 and hirudin. The independent scientific research achievements were highly recognized by industry experts.

Dr. Tan Jing from the North Sichuan Medical College has found that the incidence of coronary calcification in dialysis patients is as high as 74.09%. Vitamin K2 supplementation can effectively improve the blood vessel stiffness of patients without promoting blood clotting activity or increasing the risk of thrombosis.

Mr. Yoshida Yusaku, a consultant of SungenBio and an expert of the Japanese Pharmaceutical Society, introduced that the genetically engineered recombinant hirudin has been developed by SungenBio and Peking University. The specific activity is up to 18000ATU /mg. SungenBio has the exclusive invention patent and the world's pricing rights of hirudin, and researches and develops hirudin vacuum blood collection tubes, hirudin enteric-coated tablets, anticoagulant drugs, and skin care additives.